344 related articles for article (PubMed ID: 18086799)
21. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?
Diehl V; Behringer K
Cancer Invest; 2006 Nov; 24(7):713-7. PubMed ID: 17118782
[TBL] [Abstract][Full Text] [Related]
22. Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Konstantinou N; Symeonidis A; Karmiris T; Repoussis P; Roussou P; Dimopoulos AM; Kokoris SI; Dimitriadou EM; Kyrtsonis MC; Dimopoulou MN; Tsatalas C; Kokkinis G; Vrakidou E; Grigoraki V; Poziopoulos C; Stamatellou M; Liapis D; Georgiou G; Panayiotidis P; Pangalis GA;
Haematologica; 2006 Jan; 91(1):32-9. PubMed ID: 16434368
[TBL] [Abstract][Full Text] [Related]
23. [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality].
Huang HQ; Jiang WQ; Wang W; Xu GC; Zhang L; He YJ; Sun XF; Zhou ZM; Liu DG; Xu RH; Lin TY; Teng XY; Liu MZ; Su YS; Li YH; Lin XB; Guan ZZ
Ai Zheng; 2002 Dec; 21(12):1345-9. PubMed ID: 12520745
[TBL] [Abstract][Full Text] [Related]
24. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of bone involvement in Hodgkin lymphoma.
Feltl D; Markova J; Mocikova H; Dedeckova K; Kozak T
Neoplasma; 2008; 55(2):96-100. PubMed ID: 18237246
[TBL] [Abstract][Full Text] [Related]
26. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.
Olcese F; Clavio M; Rossi E; Spriano M; Ballerini F; Canepa L; Pierri I; Aquino S; Varaldo R; Manna A; Secondo V; Racchi O; Balleari E; Orcioni GF; Carella AM; Ghio R; Gobbi M
Ann Hematol; 2009 Sep; 88(9):855-61. PubMed ID: 19189105
[TBL] [Abstract][Full Text] [Related]
27. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
Feugier P; Labouyrie E; Djeridane M; Jenabian A; Dubruille V; Berthou C; Ghandour C; Desablens B; Chaït Y; Casassus P; Delwail V; Ifrah N; Le Mevel A; Lamy T; Brière J; Colonna P; Andrieu JM
Blood; 2004 Nov; 104(9):2675-81. PubMed ID: 15231567
[TBL] [Abstract][Full Text] [Related]
28. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.
Diepstra A; van Imhoff GW; Schaapveld M; Karim-Kos H; van den Berg A; Vellenga E; Poppema S
J Clin Oncol; 2009 Aug; 27(23):3815-21. PubMed ID: 19470931
[TBL] [Abstract][Full Text] [Related]
29. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
30. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
Diepstra A; van Imhoff GW; Karim-Kos HE; van den Berg A; te Meerman GJ; Niens M; Nolte IM; Bastiaannet E; Schaapveld M; Vellenga E; Poppema S
J Clin Oncol; 2007 Jul; 25(21):3101-8. PubMed ID: 17536082
[TBL] [Abstract][Full Text] [Related]
31. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
32. Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Sperotto A; Damiani D; Zaja F; Patriarca F; Geromin A; Cerno M; Stocchi R; Tiribelli M; Skert C; Rinaldi C; Fanin R
Adv Clin Path; 2002 Apr; 6(2):77-85. PubMed ID: 19753729
[TBL] [Abstract][Full Text] [Related]
33. Hodgkin's disease: a retrospective analysis of 15 years experience at a large referral centre.
Chandi L; Kumar L; Kochupillai V; Dawar R; Singh R
Natl Med J India; 1998; 11(5):212-7. PubMed ID: 10997167
[TBL] [Abstract][Full Text] [Related]
34. Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma.
Claviez A; Tiemann M; Lüders H; Krams M; Parwaresch R; Schellong G; Dörffel W
J Clin Oncol; 2005 Jun; 23(18):4048-56. PubMed ID: 15961758
[TBL] [Abstract][Full Text] [Related]
35. Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents.
Jones GL; Taylor PR; Windebank KP; Hoye NA; Lucraft H; Wood K; Angus B; Proctor SJ
Br J Cancer; 2007 Jul; 97(1):29-36. PubMed ID: 17533403
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
37. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis.
Landgren O; Algernon C; Axdorph U; Nilsson B; Wedelin C; Porwit-MacDonald A; Grimfors G; Björkholm M
Haematologica; 2003 Apr; 88(4):438-44. PubMed ID: 12681971
[TBL] [Abstract][Full Text] [Related]
38. Hodgkin lymphoma in Tyrol-a population-based study.
Fong D; Steurer M; Greil R; Gunsilius E; Spizzo G; Gastl G; Tzankov A
Ann Hematol; 2009 May; 88(5):449-56. PubMed ID: 18846373
[TBL] [Abstract][Full Text] [Related]
39. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
Nogová L; Reineke T; Eich HT; Josting A; Müller-Hermelink HK; Wingbermühle K; Brillant C; Gossmann A; Oertel J; Bollen MV; Müller RP; Diehl V; Engert A
Ann Oncol; 2005 Oct; 16(10):1683-7. PubMed ID: 16093276
[TBL] [Abstract][Full Text] [Related]
40. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?
Diehl V; Behringer K
Cancer Invest; 2006; 24(4):461-5. PubMed ID: 16777701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
